Sizofiran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Sizofiran
Accession Number
DB13128
Type
Small Molecule
Groups
Investigational
Description

A beta-D-glucan obtained from the Aphyllophoral fungus Schizophyllum commune. It is used as an immunoadjuvant in the treatment of neoplasms, especially tumors found in the stomach. Sizofiran has been used in trials studying the treatment of Cervical Cancer.

Synonyms
  • Sizofiranum
  • Sonifilan
Categories
Not Available
UNII
7F763NNC9X
CAS number
9050-67-3
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sizofiran.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Sizofiran.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Sizofiran.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sizofiran.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sizofiran.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Sizofiran.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sizofiran.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sizofiran.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Sizofiran.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sizofiran.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Sizofiran.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Sizofiran.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Sizofiran.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Sizofiran.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Sizofiran.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sizofiran.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Sizofiran.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Sizofiran.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sizofiran.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911426

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentCervical Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on October 20, 2016 21:31 / Updated on November 06, 2017 06:47